Emmes is excited to share the significant progress being made in clinical studies.
We also give you a look inside some of our own news.
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Company News
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes, part of Emmes Group, today announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials
Emmes, part of Emmes Group, a leading specialty tech-enabled global contract research organization (CRO), has been selected by the National Institutes of Health’s (NIH) NIDA [National Institute of Drug Abuse] to support their Clinical Trials Network (CTN) for a multi-task, IDIQ contract.
The management of NIDA Clinical Trial Network is supported by the Data and Statistical Coordinating Center (DSC) and the Clinical Coordinating Center (CCC), both done by Emmes. This new contract was awarded to Emmes ahead of two other bidders and sees that the CRO continues its long-standing partnership with the NIH – having held the previous DSC contracts since 2009 and CCC contracts since 2005.
The NIDA CTN is tasked with the goal of improving treatments and delivery for substance use disorder patients across the country. Emmes’ role as the CCC is to provide regulatory, safety, monitoring, training, and other clinical trial support and services as needed within the trials.
“We are incredibly proud to have been awarded this project by NIDA as the research they are undertaking is vital in advancing new understandings of drug addiction, potential treatments and improvements to care for patients with substance use disorders,” said Peter Ronco, CEO of Emmes.
The contract, which has a $50M ceiling, included the award of three task orders that are part of the IDIQ, NIH's National Institute on Drug Abuse Clinical Trials Network, including the NIH NIDA CTN HEAL Enhancement task; the NIH NIDA CTN Portfolio Support task; and the NIH NIDA CTN's Clinical Coordinating Center Study task.
About Emmes Group:
Emmes Group is a privately held contract research organization (CRO), wholly owned by New Mountain Capital (https://www.newmountaincapital.com). The company is transforming the future of clinical research, bringing the promise of new medical discovery closer within reach for patients. Emmes Group was founded as Emmes more than 47 years ago, becoming one of the primary clinical research providers to the US government before expanding into public-private partnerships and commercial biopharma. Today, the company is transforming the future of clinical research, by creating the industry’s first specialty, tech and AI based CRO optimized to deliver programs faster, better, and more efficiently. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.
About Emmes CRO:
Emmes CRO, founded more than 45-years ago, is a global, full-service Clinical Research Organization dedicated to the advancement of public health and biopharmaceutical innovation. Emmes CRO has supported more than 2,000 clinical trials across numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. The company has built industry leading capabilities in cell and gene therapy, vaccines and infectious diseases, ophthalmology, and neuroscience. Today, we are part of the Emmes Group, helping transform the future of clinical research. Learn more at www.emmes.com.
For media inquiries, please contact:
Dana Roche
Director, Marketing & Communications
droche@emmes.com
Rare Disease Day: Emmes Endpoints Solutions submits Duchenne video assessment qualification plan to FDA
Article
Creation of the Emmes Group Will Advance Company’s 47-year Legacy and Build Clinical Research Infrastructure for the Future
Company News
- New Business Unit Veridix AI Launched to Embed Technology and AI in Day-to-Day Clinical Operations
- Dr. Rama Kondru to Join the Emmes Group as CEO, Veridix AI
- Industry Leader Matthew Holt to Join Board of Directors
Emmes today announced the creation of the Emmes Group, with Sastry Chilukuri serving as its executive chairman and chief executive officer. The company also announced a new board member, Matthew Holt.
The Emmes Group will have two business units: Emmes, its Clinical Research Organization (CRO) led by Peter Ronco, and Veridix AI, the newly launched technology and artificial intelligence (AI) group, led by recently appointed executive Dr. Rama Kondru.
Chilukuri will share plans to build a technology- and AI-first clinical research infrastructure during his presentation this Thursday, January 11th at the J.P. Morgan Healthcare Conference.
“We have an opportunity to advance Emmes’ 47-year legacy of excellence in clinical research by building the clinical research infrastructure of the future,” stated Chilukuri. “Our new Veridix AI business unit will embed technology and generative AI into all aspects of clinical trials. Emmes is a full-service CRO with more than 1,600 employees, supporting clinical research in over 70 countries. We are one of the top clinical service providers to the U.S. government with industry-leading capabilities in cell and gene therapy, vaccines and infectious diseases, and ophthalmology.
“AI is now helping us learn the language of biology to rapidly generate disease insights and advance new treatments,” Chilukuri continued. “Our proprietary Clinical Generative AI platform, will help us build the clinical research infrastructure needed to bring these treatments to patients faster with high quality.”
The Emmes Group also added a new member to its board of directors, whose background adds strength to the new strategy. Matthew Holt is managing director and president, private equity, of New Mountain Capital, with a proven track record of rapidly digitizing and scaling healthcare service businesses.
About the Emmes Group
The Emmes Group is dedicated to advancing public health and biopharmaceutical innovation throughout the world. Our legacy CRO business Emmes, founded in 1977, provides clinical services tailored to meet the needs of its public and private sector partners. Our Veridix AI business is focused on delivering innovative technology solutions to create the clinical trial infrastructure of the 21st century. To learn more about how we are modernizing clinical research and having a positive impact on patients' lives, visit the Emmes Group website at www.theemmesgroup.com.
Dr. Rama Kondru Named Chief Executive Officer of Veridix AI
Leadership News
Dr. Kondru Brings a Formidable Blend of Scientific Expertise and Visionary Technology and Data Sciences Leadership Background to Lead the Emmes Group’s New Technology and Artificial Intelligence (AI) Business
The Emmes Group today announced that its newly launched Veridix AI business will be led by Dr. Rama Kondru as its’ Chief Executive Officer.
The creation of Veridix AI as the new and complementary partner of the Emmes Group’s legacy Clinical Research Organization (CRO) business was announced yesterday during the JP Morgan Healthcare Conference in San Francisco.
“Rama’s unique set of skills and experiences make him an outstanding addition to our team,” noted Emmes Group Executive Chairman and CEO Sastry Chilukuri. “His strong scientific, research and academic credentials, in combination with successful, C-level roles in the life sciences sector, will be especially valuable as we work to create the technology and AI platform for 21st century clinical research.”
Chilukuri added, “We have ambitious plans to accelerate Emmes’ use of generative AI and digital technology tools in our clinical research. This will be truly transformative with wide-ranging implications for how research is conducted and how solutions are built.”
According to Dr. Kondru, "In a world defined by rapid technological evolution, I was drawn to the Emmes Group's unwavering commitment to cutting-edge technology and AI. Witnessing the exponential surge in data and the maturation of AI, it's clear these forces are being intricately woven into the fabric of diverse industries. Remarkably, within life sciences, Emmes stands as a trailblazer, firmly embracing AI in a way unparalleled by other CROs. Our pioneering solutions and services are poised to address unmet medical needs and redefine the trajectory of the industry.”
“Emmes has long been recognized for its patient-centric approach," he continues. "The integration of Veridix AI marks a transformative leap in enhancing the speed and efficiency of clinical research. This is not merely about technology; it's about delivering meaningful outcomes for patients. As we unlock the vast potential within healthcare data, a Veridix AI-powered clinical trial ecosystem will play a pivotal role in directly impacting and elevating patient care.”
A leader with more than two decades of biopharma, medical device and data science experience, Dr. Kondru previously served as the co-CEO of Medidata Solutions, the leading provider of Software as a Service and data analytics solutions that support clinical research. Earlier, Dr. Kondru was senior vice president and chief information officer (CIO) for Janssen Pharmaceuticals - Americas, a Johnson and Johnson (J&J) company. He also served as the Global Head of Data Sciences at J&J. Prior to joining Janssen, he held leadership and scientific roles at UCB Pharma and Hoffmann-La Roche. He also has served as a member of the board of directors for several companies.
Dr. Kondru is a named inventor on over 29 patents, has received multiple innovation awards, and has authored more than 30+ peer-reviewed scientific publications. He holds a Ph.D. in computational sciences from the University of Pittsburgh and an undergraduate degree from the Indian Institute of Technology, Mumbai. He also completed post-doctoral research at the University of Pittsburgh Medical School and served as an adjunct professor at Duke University.
About the Emmes Group
The Emmes Group is dedicated to advancing public health and biopharmaceutical innovation throughout the world. Our legacy CRO business Emmes, founded in 1977, provides clinical services tailored to meet the needs of its public and private sector partners. Our Veridix AI business is focused on delivering innovative technology solutions to create the clinical trial infrastructure of the 21st century. To learn more about how we are modernizing clinical research and having a positive impact on patients' lives, visit the Emmes Group website at www.theemmesgroup.com.
Emmes Acquires VaxTRIALS
Company News
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the acquisition of VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.
“Today’s clinical trials are both more complex and more global in nature than ever before,” said Emmes Executive Chairman Sastry Chilukuri. “Combining VaxTRIALS’ depth of expertise in Latin America and Emmes’ strengths, particularly in technology, biostatistics and data management, will give clients an unmatched partnership experience in conducting their clinical trials.”
“VaxTRIALS is a highly complementary match for Emmes,” elaborated Emmes Chief Executive Officer Peter Ronco. “It extends our global reach from our current base in North America, Europe and Asia to Latin America, one of the fastest-growing regions for clinical trials due to its large, diverse patient population and high-quality clinical research sites. VaxTRIALS adds a number of new biopharmaceutical and public-private partnership clients and further strengthens one of our largest research therapeutic areas: vaccines and infectious diseases.”
VaxTRIALS’ vaccine-related clinical trials have been conducted in 11 Latin American countries, as well as the Philippines.
VaxTRIALS’ staff members have supported clinical trials aimed at preventing diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio and COVID-19.
“Another benefit for Emmes,” continued Ronco, “is that we’ll be able to take advantage of VaxTRIALS’ established network in Latin America to reach clinical trial participants in our other core therapeutic areas, including rare and pediatric diseases, cell and gene therapy, and ophthalmology.”
“Both our companies have built enduring customer relationships and a legacy of service in vaccine and infectious disease research,” said VaxTRIALS CEO Dr. José Jimeno. “I am proud that we have made both people and cultural development a priority, including hiring and developing employees who care deeply about making a difference in public health.
“I’m also excited to incorporate Emmes’ technology expertise, as well as legacy and depth in biostatistical analysis and data management, for the benefit of our clients throughout Latin America,” he added. “Emmes’ Advantage eClinical data management platform, with benefits including improving data quality, easing oversight of clinical trial operations, and reducing trial timelines and costs, can be extremely helpful to our customers.”
Chilukuri noted, “José Jimeno combines his background as a medical doctor with an extensive knowledge of the industry and the Latin American region and a stellar reputation in the global vaccine community. As VaxTRIALS’ founder and CEO, he has been an extremely active and energized leader. We are thrilled to welcome José and the VaxTRIALS team to Emmes.”
About VaxTRIALS
A specialized Clinical Research Organization, VaxTRIALS provides innovative solutions in managing and monitoring vaccine clinical trial activities across Latin America. Founded in 2012, VaxTRIALS has built a reputation for helping clients, sponsors and vendors achieve extraordinary results in implementation of their studies. A regional leader with an active presence in 11 LatinAmerican countries and the Philippines, the company’s local regulatory knowledge and wide network of experienced investigational sites ensures rapid trial enrollment and standards.
About Emmes
Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.
Matt Bond Has Joined Emmes as Chief Financial Officer
Leadership News
His M&A Background and Experience with Successful Private-Equity-Backed Companies Will Benefit the Company’s Growth and Diversification Strategy
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Matt Bond has become its chief financial officer (CFO).
Emmes Chief Executive Officer Peter Ronco said, “Matt combines a rich set of CFO experiences with a deep understanding of the biopharma and clinical technology solutions space. A seasoned executive with over 30 years of financial leadership experience, he has led the finance function for many successful, private-equity-backed companies in the pharmaceutical services and contract research market segment.”
“This is a perfect time to join the company, as we continue to build our reputation with government and biopharma clients and ramp up our presence in new global markets,” noted Bond. “I’m able to hit the ground running, because I’ve worked in this sector for decades and have been successful in generating profitable growth while partnering with great management teams.”
Before joining Emmes, Bond was the CFO of Bracket (now Signant Health), a leading technology provider to the drug development market. There, he led the organization through a period of sustained growth, including a successful sale of the company to another global, private-equitybacked firm. Before that, he was a founder and served as CFO of Aptiv Solutions, a technologyfocused CRO. Bond was part of the leadership team that grew the business from a startup to a large multinational organization through the acquisition of more than 10 companies.
Previously, Bond was executive vice president and CFO of PRA, a global CRO, where he led a successful initial public offering. Earlier in his career, Matt was vice president of finance with Marriott International and a consultant with a leading, global financial consulting firm. He holds a B.S. degree from Wake Forest University.
Ronco said, “We are pleased to have Matt join our team. His hands-on experience with mergers and acquisitions will be a great help as we continue to identify, review and assimilate companies that complement our strengths and accelerate our global growth.”
About Emmes
Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.
Emmes Introduces Telehealth Capabilities into Advantage eClinical
Company News
The latest upgrade is part of wider goals to create the industry’s first unified digital data platform for decentralized and hybrid trials
Rockville, MD, September 27, 2023 – Emmes, a global, full-service Contract Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces the addition of telehealth capabilities within Advantage eClinical. The new application means any scheduled visit can become virtual with video calls augmented directly through the platform and patients signing in through their existing participant portal. Advantage eClinical is designed to enable a simple, intuitive experience that fits seamlessly into the everyday lives of study participants and sites.
The addition of telehealth capabilities is part of a much wider development plan for Emmes’ third generation clinical data platform. The company’s vision is to create the first unified, flexible, digital trial infrastructure that minimizes disruption for sites and participants and is more accessible. Our single, flexible platform accommodates all trial modalities – traditional, decentralized including hybrid and fully virtual – as well as the needs of patients, sponsors and sites. It also includes all tasks from data capturing, cleaning, monitoring, to workflow management, sample tracking and even clinical assessment and engagement tools.
“What we are building with Advantage eClinical is more than an EDC or eCOA/ePRO. It’s a platform to accelerate the delivery of all types of trial designs through one unified, modular system. 90% of respondents in the Center for Information and Study on Clinical Research Participation’s (CISCRP) 2021 Perception and Insights Study stress the importance of having options for completing study visits, such as virtual and home visits. By eliminating the need for sponsors to procure and set up additional point decentralized trial (DCT) systems, we hope more studies will offer patient-centric options for patients to participate,” commented Ching Tian, chief innovation officer at Emmes.
Ashley Davidson, Emmes associate vice president, product management and operations, explained that the telehealth application makes workflow far simpler for site staff because all information is on screen at the same time, including assessment forms and patient records. She added, “It gives that real world feel of an in-person visit and enables simultaneous note-taking and record-checking. On a more practical level, operating a decentralized or hybrid trial design means we can also open up trials to more diverse groups of participants, which has been a big driver from the regulators.”
Advantage eClinical is cloud-based and 21 CFR Part 11, GDPR and HIPAA compliant. It is available as a standalone product – software as a service (SaaS) – for any biopharma customer and CRO, and has supported more than 1,000 trials, for nearly one million patients in over 70 countries, spanning more than 31,000 clinical trial sites.
About Emmes
Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.
For media enquiries, please contact:
Alex Heeley or Nidhi Narain
De Facto Communications
T: +44 (0) 203-735-8165
E: a.heeley@defacto.co.uk / n.narain@defacto.co.uk
Emmes Appoints Peter Ronco as Chief Executive Officer
Leadership News
Ronco’s Global Pharmaceutical Experience Will Support the Next Chapter of Emmes’ Growth and Technology Enablement
Rockville, MD, September 20, 2023 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Peter Ronco has been named Chief Executive Officer, effective immediately.
Mr. Ronco succeeds Dr. Christine Dingivan, who will serve as a senior advisor to Executive Chairman Sastry Chilukuri, and Emmes’ Board of Directors.
“Emmes has a 45-year legacy of scientific innovation and advancing public health. Peter’s leadership and operational expertise in the life sciences sector will be invaluable in our next phase of growth. I am excited to welcome Peter to the Emmes team,” said Kyle Peterson, Managing Director at New Mountain Capital and member of the Board of the Directors of Emmes. “We are grateful for Christine’s leadership through an important chapter of growth and diversification after taking over from the original founders. She is a remarkable physician-entrepreneur and industry leader and will continue to support Peter, Sastry and the Board going forward.”
“Peter is a seasoned and innovative life sciences leader. He brings deep experience in running global operations with frontline use of technology and data science, which will propel our company forward,” added Mr. Chilukuri.
Mr. Ronco is a global pharmaceutical executive with experience in a number of R&D leadership positions over more than two decades. He most recently served as Senior Vice President, Global Development at Johnson & Johnson, responsible for the design and delivery of a drug development portfolio of more than 500 active clinical studies across all therapeutic areas and phases of development. He has also held senior roles with Bristol Myers-Squibb, Accenture and Pfizer.
“I am thrilled to be joining a company with an outstanding scientific track record and extensive credibility in clinical research,” said Mr. Ronco. “Emmes has a storied history, addressing some of the most complex health issues of our time. We look forward to an exciting future together as we partner with patients, clinical sites, government agencies and biopharmaceutical companies to advance the next phases of scientific innovation and change the trajectory of health care.
“I believe that advances in decentralized clinical trials, data science, and generative AI offer huge potential to make clinical research even faster and more patient-focused. Embracing and accelerating the uptake of these approaches will allow us to have a greater impact on global health and biopharma innovation in the discovery and development of new medicines.”
Mr. Ronco is a graduate of Nottingham University in the United Kingdom and will be based out of Emmes’ Rockville, Maryland, headquarters.
About Emmes
Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.
About New Mountain Capital
New Mountain Capital is a New York-based investment firm that emphasizes business building and growth, rather than debt, as it pursues long-term capital appreciation. The firm currently manages private equity, credit, and net lease real estate funds with over $45 billion in assets under management. New Mountain seeks out what it believes to be the highest quality growth leaders in carefully selected industry sectors and then works intensively with management to build the value of these companies. For more information on New Mountain Capital, please visit www.newmountaincapital.com.
Contacts:
Company: Lynn Lewis
301-251-1161
llewis@emmes.com
Media: Karen Vahouny
703-624-2674
kvahouny@gmail.com
For New Mountain Capital
Dana Gorman / Matthew Butler
H/Advisors Abernathy
212-371-5999
dana.gorman@h-advisors.global / matthew.butler@h-advisors.global
Kristin Judge Joins Emmes as Chief Growth Officer
Leadership News
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Kristin Judge has joined as its chief growth officer, a newly created executive leadership position.
Emmes Chief Executive Officer Dr. Christine Dingivan said, “Kristin’s experience is a perfect fit for Emmes, given her accomplishments across CRO and life sciences sales. She has consistently led her teams in surpassing annual sales goals and building a workplace environment that fosters teamwork, collaboration and success. Her technology sales background will also be especially useful as we expand our Advantage eClinical platform, which optimizes our clients’ investments in IT and informatics.”
In this new position, Judge will lead business development and all sales support activities, including inside sales and proposal development. She will support both public sector and biopharma groups.
Before joining Emmes, Judge was the head of CRO and clinical data management systems sales at Veeva Systems, leading a global team responsible for more than 200 customers across both the CRO and biotech sectors. Prior to her position at Veeva, she worked for Labcorp Drug Development, leading a global sales team focused on building large pharmaceutical relationships. Judge was also responsible for the expansion of one of Labcorp's largest full-service partnerships.
She began her career at PPD, where she gained clinical operations and sales experience during her eight-year tenure. After creating the company’s first inside sales group, her role was expanded to leading sales for PPD’s full-service offerings to all industry segments. There, Judge managed one of the largest partnerships at the company and received numerous awards for her significant contributions to the company’s growth.
“What attracted me to Emmes was the fact that it is considered best-in-class in the niches it has selected,” said Judge. “Plus, having worked with some of the company’s leaders in my prior roles also made this a very compelling opportunity. The company’s passion for the role it plays in clinical research, the long-held client relationships, and commitment to authenticity were major selling points for me.”
Over the past six months, Emmes has recruited five senior leaders to support its growth and diversification efforts. In addition to Judge, these include Becky Marson as chief people and performance officer; Matt Honan, vice president and global head of corporate development; Wendy Buckland, chief operating officer; and Ching Tian, chief innovation officer.
Dr. Dingivan noted, “I’m confident that the establishment of the chief growth officer position to spearhead our sales efforts and the recruitment of Kristin, given her 15 years of experience in both CRO and life sciences sales, will add immediate value to Emmes.”
About Emmes
Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.
Emmes Applauded by Frost & Sullivan for Streamlining Clinical Trials and for Its Competitive Strategies
Research News
Emmes collaborates with pharmaceutical companies as strategic partners, providing one-stop clinical trial services, reducing costs, and accelerating development.
SAN ANTONIO, TX. – April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.
Emmes is a full-service, global Clinical Research Organization (CRO) committed to promoting public health and biopharmaceutical innovation. Its dedication to problem-solving, close collaboration with customers, and scientific excellence help its customers better understand complex research problems, generate higher-quality data, and enable better treatment options. The company has extensive therapeutic experience in common and rare diseases, which is backed up by specialized knowledge in biostatistics, biomedical data science and bioinformatics, and eClinical technologies.
The company collaborates with biopharmaceutical, governmental, non-profit, and academic organizations to enhance its value proposition and meet client demands. The company brings a solid statistical approach to every clinical study phase, such as protocol development, statistical analysis, and publishing. Over 200 data managers work with clinical research associates to review data and flag any potential issues throughout the clinical trial process.
Emmes’ executive sponsors in charge of strategy alignment link broader objectives with individual goals at the executive committee level. The company has a traceable roadmap to success in three strategic priorities: geography, therapeutic expertise, and technology. Moreover, it assesses the outcome measures at the end of the year, resulting in significant strides and clever growth strategies.
Unmesh Lal, industry analyst at Frost & Sullivan, stated, “Emmes’ experience in well-differentiated clinical research communities and longstanding strength in biostatistics empowers it to assist customers with innovative study designs, regulatory strategies, and full-service worldwide clinical trial execution capabilities.”
Emmes Chief Executive Officer Dr. Christine Dingivan said, “This award recognizes the efforts of everyone who works at Emmes. It reflects a successful transition, in only 2.5 years, to become a truly global company with a diverse mix of public sector and biopharma clients. We’re continuing to differentiate ourselves in the market, building upon our long history of close client partnerships and deepening our research capabilities in a number of therapeutic areas.”
She continued, “The fact that Frost & Sullivan conducted an independent review of the CRO industry and selected Emmes is extremely gratifying recognition for all of us.”
Emmes’ disciplined science, rigorous research, fact-based decision-making, and operational excellence has earned the company a sterling reputation. Its Advantage e-Clinical platform uses a distinctive cloud architecture that quickly adapts to internet, mobile, and telemedicine approaches, improving its growth strategies, revenue rates, company size, and profit verticals. The company showcases high discipline in capital allocation, prioritizing its talented workforce by increasing salaries and improving benefits programs. As a result, Emmes has a 100% success rate in governmental recompete contracts and is becoming a global leader while maintaining its commitment to excellence, data analytics, and specialty areas. Overall, its transparent, non-adversarial, and frictionless approach and its close relationships position Emmes as a natural partner of choice.
“Emmes’ focused approach helps it outpace competitors, securing its position as a trusted partner and market leader. Its public and private healthcare industry intersection uniquely positions the company to support customers with cutting-edge study designs, biostatistics scientific expertise, regulatory strategies, and full-service global clinical trial execution capabilities,” added Manuel Albornoz, best practices research analyst at Frost & Sullivan.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Ashley Weinkauf
P: 210-844-2505
About Emmes
Founded more than 45 years ago, Emmes is a global, full-service Clinical Research Organization dedicated to excellence in supporting the advancement of public health and biopharmaceutical innovation. The company’s clients include numerous agencies and institutes of the U.S. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. To learn more about how our research is making a positive impact on human health, go to the Emmes website at www.emmes.com.
Contacts: Company: Lynn Lewis
P: 301-251-1161
Media: Karen Vahouny
P: 703-624-2674
E: kvahouny@gmail.com
